Amneal to Acquire Kashiv BioSciences to Expand Global Biosimilars Platform

The acquisition brings together Kashiv’s expertise in biosimilar development and manufacturing with Amneal’s commercial scale and distribution capabilities.

Amneal Pharmaceuticals has entered into a definitive agreement to acquire Kashiv BioSciences, in a move aimed at expanding its capabilities in the biosimilars segment.

The transaction is subject to shareholder approval, regulatory clearances, and customary closing conditions, and is expected to be completed in the second half of 2026.

The acquisition brings together Kashiv’s expertise in biosimilar development and manufacturing with Amneal’s commercial scale and distribution capabilities.

Kashiv, headquartered in Piscataway, New Jersey, operates across the U.S. and India, with capabilities spanning research and development, clinical operations, manufacturing, and regulatory functions.

Amneal, based in Bridgewater, New Jersey, currently manages a portfolio of approximately 300 generic, specialty, and biosimilar medicines, with a significant presence in the U.S. affordable medicines market. The company delivers over 160 million prescriptions annually, primarily in the United States.

Executives from both companies highlighted the growing opportunity in the biosimilars market, particularly in the U.S., where a wave of biologics is expected to lose exclusivity in the coming years. The combined entity is expected to operate as a fully integrated biosimilars platform, covering the end-to-end lifecycle from development to commercialization.

Kashiv has developed multiple biosimilars and is among a limited number of U.S.-based companies with both manufacturing capabilities and marketing authorizations in this segment. The company also maintains a pipeline of clinical-stage assets, which is expected to complement Amneal’s existing portfolio.

The transaction builds on an existing partnership between the two companies spanning over a decade. Post-acquisition, the combined platform is expected to support a broader pipeline of biosimilars and enable scaling of product launches across key markets.

Advisors for the transaction include J.P. Morgan as financial advisor to Kashiv, with Holland & Knight LLP and Dhinal Shah Associates serving as legal counsel.

Stay tuned for more such updates on Digital Health News